Blood Plasma Articles & Analysis
22 news found
The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a simple blood draw is less invasive than a traditional biopsy, helping to simplify patient monitoring and more quickly guide clinical decision-making. ...
Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). This non-invasive testing allows for cancer genomic profiling and disease monitoring. ...
The primary objective is to evaluate the absorption of buspirone and the presence of metabolite 1-pyrimidinylpiperazine (1-PP) in blood plasma from time delayed formulations and correlate with scintigraphic time and site of release. ...
“With patient enrollment complete and data analysis underway, we aim to show that the implications of COVID as an endothelial disease utilizing this measure along with precise measurement of total blood, red cell and plasma volume could help guide the care of COVID-19 patients, thus promoting better treatment of these ...
The study, titled “Blood volume and albumin transudation in critically-ill COVID-19 patients,” showed that COVID-19 patients suffer from significant capillary damage and blood volume deficits that care teams became aware of only through the use of the Daxor BVA-100 blood test. ...
” In heart failure, physicians seek to optimize a patient’s blood volume which has wide variations in total blood volume (TBV), plasma volume (PV) and red blood cell volume (RBCV). ...
SAGAsafe® is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify sequence variants in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance. SAGAsafe® is part of a portfolio of ultrasensitive technologies, which ...
” In addition, The Journal of the American Medical Association Neurology published findings from BioFINDER’s large comparison of blood plasma amyloid-beta assays. One of the types of assays included in the study was the liquid chromatography–mass spectrometry (LC-MS/MS) assay that Dr. ...
C2N under a technology transfer agreement with Washington University, developed this mass spec assay into the PrecivityAD™ blood test. BioFINDER’s large comparison of blood plasma amyloid-beta assays found that the Washington University assay performed the best out of seven assays, including in the measurement of phosphorylated ...
SAGAsafe is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify mutations in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance. The analyses will be run in the SAGA Diagnostics central laboratory in Lund, Sweden. ...
Latvian COVID-19 cohort includes various types of samples (blood, serum, plasma, oropharyngeal swabs, PBMC, feces, urine, isolated DNA, RNA), molecular data (blood biochemistry, cytokine panel, genome-wide genotyping, viral genome data, metagenome, metabolome, and transcriptome data) as well as excessive characterization of each clinical case. ...
This assay aims to provide deep analysis of the human plasma proteome for detection and characterization of novel prostate cancer biomarkers. ...
The test detects specific SARS CoV2 IgG and IgM antibodies in the blood in response to a coronavirus infection. The detection of antibodies can be used to identify those who have already had contact with the virus. ...
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. ...
ByDiamiR
Several governments around the world, including the U.S. and Spain, consider Grifols’ manufacturing plants and plasma-and blood-donation centers as essential infrastructures. For this reason, the donors and personnel that make these donations possible are exempt when restrictions are placed on movement. Over the last years, Grifols invested heavily to ...
In 2019, the company had a total of 28 registered products: five Bioscience Division products and 23 Diagnostic Division products, of which eight are NAT donor-screening solutions utilized for blood and plasma donations and 15 are blood-typing solutions. Grifols will continue its efforts to expand its portfolio of registered products in China ...
Revenues generated from transfusion medicine solutions continue to drive the division´s performance with a positive upward trend in NAT donor-screening solutions, used to detect viruses in blood and plasma donations, blood typing and recombinant proteins. The Hospital Division’s revenues expanded by 12.5% (12.1% cc) to EUR 134 ...
The patented models enable the rapid freezing of blood plasma to a core temperature below -30°C, with two freezing plates inclined at 5°. Studies showed that this creative design better preserves the quality of the donated blood plasma. ...
Materials that do not come into direct contact with organisms, such as plasma bag, blood transfusion and transfusion equipment, syringe, operating room supplies, etc.; 2. ...
ETG-LGR instruments provide fast measurements of isotopic ratios (δ2H, δ17O, δ18O, δ13C) in blood, urine, plasma, saliva and breath. No longer limited by time consuming sample preparation, equilibration, or pre-concentration processes, fast and precise measurements may be obtained by untrained personnel in real time at a fraction of the ...